Pharmacogenetics of clinical response to risperidone

Adrián Llerena, Roland Berecz, Eva Peñas-Lledó, Ágnes Süveges, Humberto Fariñas

Research output: Contribution to journalReview article

29 Citations (Scopus)


Despite risperidones proven safety and efficacy, existing pharmacogenetic knowledge could be applied to improve its clinical use. The present work aims to summarize the information about genetic polymorphisms affecting risperidone adverse reactions and efficacy during routine clinical practice. The most relevant genes involved in the metabolism of the drug (i.e., CYP2D6, CYP3A and ABCB1) appear to have the greatest potential to predict differences in plasma concentrations of the drug and its interactions, but also relate to side effects, such as neuroleptic syndrome, weight gain or polydipsia. Other genes that have been found in association at least twice with any adverse reactions including metabolic changes, extrapyramidal symptoms or prolactine increase are: 5HT2A; 5HT2C; 5HT6; DRD2; DRD3; and BDNF. Some of these genes (5HTR2A, DRD2 and DRD3), along with 5-HTTLPR and COMT, have also been reported to be related with negative clinical outcomes. However, there is not yet enough evidence to support their routine screening during clinical practice.

Original languageEnglish
Pages (from-to)177-194
Number of pages18
Issue number2
Publication statusPublished - Jan 1 2013



  • biomarkers
  • clinical outcome
  • pharmacogenetics
  • risperidone
  • side effects

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Llerena, A., Berecz, R., Peñas-Lledó, E., Süveges, Á., & Fariñas, H. (2013). Pharmacogenetics of clinical response to risperidone. Pharmacogenomics, 14(2), 177-194.